1. In re Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724)

🔹 Background

This is the largest ongoing antitrust multidistrict litigation (MDL) involving dozens of pharmaceutical companies (manufacturers + distributors).

Plaintiffs (hospitals, insurers, pharmacies) allege:

• Price fixing of generic drugs
• Market allocation agreements
• Bid rigging in the pharmaceutical supply chain

Defendants include major manufacturers and distributors such as Teva, Sandoz, and others.

🔹 Legal Issues

• Whether parallel price increases among competitors = illegal conspiracy
• Whether “hub-and-spoke” conspiracy existed (manufacturers coordinating via intermediaries)
• Whether distributors participated in facilitating collusion

🔹 Court Findings (key rulings)

Courts held that plaintiffs plausibly alleged:

• A horizontal price-fixing conspiracy (per se illegal under Sherman Act §1)
• Evidence included:
  • Sudden synchronized price hikes
  • Text messages and executive communications
  • Market behavior inconsistent with competition

🔹 Importance

This case is central because it shows how:

Pharmaceutical supply chains can become “coordination networks” rather than competitive markets.

2. United States v. Teva Pharmaceuticals USA Inc. (DOJ Criminal Antitrust Case)

🔹 Background

The U.S. Department of Justice charged Teva and Glenmark Pharmaceuticals for colluding to fix prices of generic drugs like pravastatin.

🔹 Legal Violations

• Sherman Act §1 violations:
  • Price fixing
  • Bid rigging
  • Customer allocation

🔹 Key Facts

• Executives allegedly agreed to:
  • Increase prices simultaneously
  • Avoid competing on certain drugs
• Conduct occurred in the U.S. generic drug supply chain (2013–2015)

🔹 Outcome

• Deferred prosecution agreements (DPAs)
• Large financial penalties
• Cooperation agreements with DOJ

🔹 Legal Principle

The court reinforced:

Price-fixing in pharmaceuticals is per se illegal, meaning no need to prove market impact.

3. FTC v. Cardinal Health, Inc. (Radiopharmaceutical Monopoly Case)

🔹 Background

The FTC alleged that Cardinal Health monopolized radiopharmaceutical distribution markets in multiple U.S. cities.

Radiopharmaceuticals = diagnostic drugs used in hospitals (e.g., heart imaging agents)

🔹 Legal Issue

• Whether Cardinal engaged in illegal monopolization under Sherman Act §2

🔹 Conduct Alleged

• Acquiring competitors to dominate local markets
• Excluding rival radiopharmacies
• Locking up supplier distribution rights

🔹 Court/FTC Findings

• Cardinal obtained de facto monopoly in 25 markets
• Hospitals were forced to pay inflated prices

🔹 Outcome

• Settlement of $26.8 million
• Injunctions preventing exclusionary conduct

🔹 Legal Principle

This case shows:

Even local medical supply distribution can form a “monopoly market” under antitrust law.

4. In re Generic Pharmaceuticals Pricing Antitrust Litigation (Distributor Liability – McKesson, AmerisourceBergen, Cardinal Health)

🔹 Background

Hospitals and pharmacies sued major distributors:

• McKesson
• AmerisourceBergen (now Cencora)
• Cardinal Health

🔹 Allegations

• Facilitating price-fixing by manufacturers
• Ignoring suspicious pricing patterns
• Acting as “conduits” in collusion networks

🔹 Legal Issue

• Can distributors be liable in a hub-and-spoke conspiracy?

🔹 Court Analysis

Courts examined:

• Whether distributors knowingly participated in coordinated pricing
• Whether they “facilitated information exchange”

🔹 Key Result

Some claims were dismissed, but courts allowed others to proceed under:

• Section 1 conspiracy theory
• Aiding and abetting theories in civil antitrust suits

🔹 Legal Principle

Even non-manufacturer supply chain actors can be liable if they knowingly enable collusion.

5. Marion Healthcare LLC v. Becton Dickinson & Co. (Seventh Circuit, 2020)

🔹 Background

Healthcare providers sued Becton Dickinson (medical device manufacturer) and distributors.

🔹 Allegations

• Price fixing of medical supplies
• Use of Group Purchasing Organizations (GPOs) to suppress competition

🔹 Legal Issue

• Whether indirect purchasers have standing under Illinois Brick doctrine

🔹 Court Holding

The Seventh Circuit ruled:

• Plaintiffs (hospitals) do have antitrust standing
• Supply chain intermediaries (GPOs/distributors) do not break causal chain

🔹 Legal Principle

Medical supply chain complexity does NOT shield antitrust liability.

6. FTC v. AmerisourceBergen / Opioid Distribution Litigation

🔹 Background

DOJ and civil lawsuits alleged that distributors:

• Failed to report suspicious opioid orders
• Continued supplying high-risk pharmacies

🔹 Antitrust Angle

Although primarily opioid/public health litigation, antitrust issues arise in:

• Distribution control over controlled substances
• Market failure due to concentration in three wholesalers:
  • McKesson
  • Cardinal Health
  • AmerisourceBergen

🔹 Legal Theory

• Failure to police supply chain = facilitation of unlawful market distortion
• Potential violation of Section 2 (monopoly maintenance) and regulatory obligations

🔹 Outcome

• Massive settlements (~billions of dollars across states)
• Ongoing litigation structure

7. GoodRx / PBM Antitrust Litigation (Pharmacy Benefit Managers Case)

🔹 Background

Pharmacies and consumers sued PBMs:

• CVS Caremark
• Express Scripts
• OptumRx
• GoodRx

🔹 Allegations

• Coordinated suppression of pharmacy reimbursements
• Inflating drug prices through rebate systems

🔹 Legal Issue

• Whether PBMs form a price coordination cartel

🔹 Court Focus

• Whether rebate structures distort competition
• Whether PBMs act as “price-setting intermediaries”

🔹 Legal Principle

Antitrust scrutiny extends beyond manufacturers to financial intermediaries controlling drug pricing flows.

CORE LEGAL THEMES ACROSS ALL CASES

1. Hub-and-Spoke Conspiracies

• Manufacturers = “spokes”
• Distributors/PBMs = “hub”
• Courts analyze whether hub knowingly coordinated pricing

2. Vertical + Horizontal Collusion

• Horizontal: competitor manufacturers agreeing on prices
• Vertical: distributors facilitating coordination

3. Monopoly in Distribution Networks

• Even regional medical supply control can trigger Section 2 liability

4. Indirect Purchaser Standing

• Courts increasingly allow hospitals/pharmacies to sue despite intermediaries

5. Structural Concentration Problem

• U.S. medical supply chain dominated by:
  • 3 wholesalers
  • 3 PBMs
    → This concentration increases antitrust risk

FINAL SUMMARY

Medical supply chain antitrust litigation shows a consistent pattern:

The pharmaceutical supply chain is legally treated as a single interconnected competitive system, not isolated layers of manufacturers, distributors, and pharmacies.

Courts now aggressively examine:

• coordination signals across supply chain actors
• pricing parallelism
• exclusionary distribution practices
• intermediary roles (PBMs, GPOs, wholesalers)